Clinical Trial 23578

• Overview

  Study Title:

  A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4)

  Summary:

  This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation.

  Objective:

  Primary *To compare PFS of adagrasib + pembrolizumab + chemotherapy to placebo + pembrolizumab + chemotherapy *To compare OS of adagrasib + pembrolizumab + chemotherapy to placebo + pembrolizumab + chemotherapy Secondary *To assess OR of adagrasib + pembrolizumab + chemotherapy and placebo + pembrolizumab + chemotherapy *To assess DOR of adagrasib + pembrolizumab + chemotherapy and placebo + pembrolizumab + chemotherapy *To assess PFS of adagrasib + pembrolizumab + chemotherapy and placebo + pembrolizumab + chemotherapy *Characterize the safety and tolerability of adagrasib + pembrolizumab + chemotherapy and placebo + pembrolizumab + chemotherapy *To assess differences in disease-related symptoms between treatment arms *To characterize differences in changes in cancer-related symptoms and quality of life between treatment arms

• Treatments

  Therapies:

  Chemotherapy (NOS); Immunotherapy; KRAS G12C inhibitor

  Medications:

  Adagrasib/Placebo (); Alimta (Pemetrexed); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin (); cisplatin ()

• Inclusion Criteria

  Inclusion Criteria:
  • Histologically or cytologically confirmed diagnosis of non-squamous NSCLC with evidence of KRAS G12C mutation via tumor sample and/or circulating tumor deoxyribonucleic acid (ctDNA).
  • Locally advanced or metastatic disease.
  • Measurable disease via computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria of at least 1 lesion.
  • No prior systemic anti-cancer therapy given for advanced or metastatic disease.
  • Not a candidate for definitive therapy (eg, chemoradiation or complete surgical resection).
  • Participants with brain metastases are eligible for enrollment, including those with untreated brain metastases. Brain metastases must be asymptomatic and not in need of immediate local therapy. Any untreated brain metastases must be ≤ 20 mm in diameter.
  • Any PD-L1 expression (0 to 100%) as determined by VENTANA PD-L1 (SP263) assay, Agilent PD-L1 IHC 22C3 pharmDx, or Agilent PD-L1 IHC 28-8 pharmDx.

• Exclusion Criteria

  Exclusion Criteria:
  • Participants with an active autoimmune or inflammatory disease requiring systemic treatment within 2 years.
  • Uncontrolled or significant cardiovascular conditions within 6 months prior to enrollment that are ongoing or with risk of recurrence.
  • Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities.
  • Ongoing treatment with concomitant medication known to cause prolonged QTc interval and that cannot be switched to alternative treatment prior to study entry.
  • Treatment targeting KRAS G12C mutation (eg, sotorasib, adagrasib) in any setting.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.